Danaher Co-Founders Waive 1M RSU Grants; Board Appoints Two New Directors

Executive Summary

On October 13, 2026, Danaher Corporation (NYSE: DHR) filed a Form 8-K disclosing significant corporate governance updates and an equity award surrender by its co-founders under Items 5.02 and 8.01.

1. Waiver of Founder RSUs (Item 8.01)

• Context: On August 4, 2026, Steven M. Rales (Chairman of the Board) and Mitchell P. Rales (Chairman of the Executive Committee) were each granted 500,000 Restricted Stock Units ("Founder RSUs") alongside stock option awards.
• Event: Effective October 9, 2026, both Steven M. Rales and Mitchell P. Rales unconditionally waived their rights to the 500,000 Founder RSUs each (aggregating 1,000,000 RSUs) for no consideration.
• Market Implications: The voluntary surrender eliminates substantial potential shareholder dilution and removes perceived governance concerns surrounding large founder mega-grants.

2. Board Changes & Refreshment (Item 5.02)

• Board Expansion: The Board increased its size from 11 to 13 members.
• Appointments:
  • Daniel L. Comas (Age 62): Former Danaher EVP (2005–2020) and CFO (2005–2018). His existing strategic consulting agreement (under which he earned $525,000 in 2025 and $393,750 in 2026) was terminated effective September 30, 2026, ahead of joining the Board.
  • Robert M. Hershberg, M.D., Ph.D. (Age 63): Former President, CEO, and Chairman of HilleVax, Inc. and former Chief Scientific Officer of Celgene Corporation. Appointed to the Science and Technology Committee.
• Retirement: Alan G. Spoon notified the Board of his planned retirement effective at the 2027 Annual Meeting of Shareholders, with no disagreements cited.

3. Investor Takeaway

The voluntary forfeiture of 1,000,000 RSUs by the Rales brothers demonstrates alignment with institutional shareholders. The addition of Dan Comas restores deep organizational and capital-allocation expertise, while Dr. Hershberg bolsters Danaher’s life sciences and biotechnology oversight.